Case Management Accelerates Shipment For SCN1A+ Dravet Syndrome Gene Therapy

ETX101, developed by Encoded Therapeutics, is an innovative investigational gene therapy designed as a one-time, potentially disease-modifying treatment for pediatric patients with Dravet syndrome caused by mutations in the SCN1A gene. The therapy is intended to address the underlying cause of the disorder by restoring gene expression, with the goal of significantly reducing or eliminating seizure frequency, slowing or preventing the progression of neurodevelopmental symptoms, and improving overall quality of life for affected children and their families.

ETX101 is administered directly into the brain, with dosing tailored to each patient based on cerebrospinal fluid volume to help ensure precise and effective delivery. Because of the highly sensitive nature of gene therapies and the complexity of intracranial administration, the treatment requires tightly coordinated logistics to ensure it reaches clinical sites safely and on schedule.

To address these challenges, Encoded Therapeutics partnered with Catalent and its Case Management Services team to support the secure and timely delivery of ETX101 for clinical study use. The collaboration focused on minimizing shipment times, reducing logistical risk, and providing continuous oversight of the supply chain to ensure that each vial arrived at the clinical site exactly when needed. By leveraging specialized expertise in advanced therapy logistics and real-time shipment management, Catalent delivered a streamlined, end-to-end solution that helped safeguard study timelines and ensured that patients with urgent medical needs could receive treatment without delay.